Axiology has created the world's first zero waste balmies by removing the classic lipstick tube. Check out more of their story on this episode of "Sustainability Week".
Axiology has created the world's first zero waste balmies by removing the classic lipstick tube. Check out more of their story on this episode of "Sustainability Week".
Sri Lanka’s top court has decided that some provisions of legislation to set up a powerful economic commission in a Chinese-built port city violate the constitution and require approval by a public referendum to become law. At the center of the dispute are fears that the $1.4 billion port city, part of China's sweeping Belt and Road infrastructure initiative, could become a virtual Chinese outpost or colony. Parliament Speaker Mahinda Yapa Abeywardena read out the Supreme Court's ruling on the Colombo Port City Economic Commission Bill on Tuesday.
(Bloomberg) -- U.S. futures rose with stocks Tuesday as optimism that economic reopenings will boost growth outweighed concern about a pick-up in virus cases in parts of Asia. The dollar dipped and oil gained.Contracts on all three U.S. equity benchmarks advanced, led by those on the Nasdaq 100 Index after tech shares slid Monday. Retailers Walmart Inc. and Macy’s Inc. climbed in premarket trading after raising their full-year guidance, while Home Depot Inc. gained as its results beat estimates. Commodity and automotive shares boosted the Stoxx Europe 600 Index, while Asian equities also climbed.The dollar fell toward a four-month low, while U.S. 10-year Treasuries were steady as investors awaited key housing data ahead of minutes due Wednesday from the Federal Reserve’s last meeting. Brent crude at one point topped $70 a barrel in London for the first time since March on signs that reopenings are boosting demand.Stocks have been volatile after climbing to a record in early May as investors assessed economic growth prospects against a Covid-19 resurgence in countries including India. Traders will also parse the Fed minutes for policy discussion about inflation and hints of a timeline for reducing stimulus, after Vice Chair Richard Clarida said Monday that the weak U.S. jobs report showed the economy had not yet reached the threshold to warrant scaling back asset purchases.Global investor sentiment is “unambiguously bullish,” Bank of America Corp. strategists led by Michael Hartnett said, citing the firm’s latest fund manager survey. Inflation topped the list of the biggest tail risks, followed by a bond market taper tantrum and asset bubbles, while Covid-19 was only in fourth place.Elsewhere, Bitcoin was steady following volatility spurred by comments from Tesla Inc.’s Elon Musk. Coinbase Global Inc. fell in premarket trading after Monday’s drop below the reference price used in its April direct listing. AMC Entertainment Holdings Inc. advanced 6.9%, extending its longest rally since 2019.Here are some key events this week:The Fed publishes minutes from its April meeting Wednesday, which may provide clues to officials’ views on the recovery and how they define “transitory” when it comes to inflationEIA crude oil inventory report WednesdaySt. Louis Fed President James Bullard and Atlanta Fed President Raphael Bostic to speak at separate events WednesdayIMF Managing Director Kristalina Georgieva and ECB President Christine Lagarde speak at the Vienna Economic Dialogue ThursdayAustralia unemployment rate ThursdayEuro-area finance ministers and central bank chiefs hold an informal meeting. A larger group of EU finance ministers and central bank chiefs will meet May 22These are some of the main moves in markets:StocksFutures on the S&P 500 rose 0.2% as of 7:29 a.m. New York timeFutures on the Nasdaq 100 rose 0.5%Futures on the Dow Jones Industrial Average rose 0.1%The Stoxx Europe 600 rose 0.3%The MSCI World index rose 0.5%CurrenciesThe Bloomberg Dollar Spot Index fell 0.3%The euro rose 0.5% to $1.2209The British pound rose 0.4% to $1.4188The Japanese yen rose 0.2% to 109.02 per dollarBondsThe yield on 10-year Treasuries was little changed at 1.64%Germany’s 10-year yield was little changed at -0.12%Britain’s 10-year yield was little changed at 0.87%CommoditiesWest Texas Intermediate crude rose 0.2% to $66 a barrelGold futures were little changedMore stories like this are available on bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Covid-19 vaccines can reduce symptoms of Long Covid, a new study has found. A team of researchers discovered that mRNA vaccines, such as Pfizer/BioNTech or Moderna, were the most effective in alleviating some symptoms of the condition. Long Covid, or post-Covid-19 syndrome, affects survivors of the virus even if they've only had mild symptoms when infected, and signs of the condition, including fatigue, insomnia, skin rashes, and brain fog, can last for weeks, if not months. The researchers analysed more than 800 people in the study, who all suffered from Long Covid, and participants were asked to wait a week after receiving their first vaccine before recording their responses. Results showed that 56.7 per cent of respondents experienced an overall improvement in symptoms, with 24.6 per cent unchanged and 18.7 per cent reporting an increase in their symptoms. Those who had Pfizer/BioNTech or Moderna vaccines had more improvements in symptoms, with the latter reducing fatigue, brain fog and muscle pain, compared with those who had the Oxford/AstraZeneca jab. Analysis author Ondine Sherwood, from LongCovidSOS, said the data was "very encouraging", but researchers were unaware of how long the effects would last. Dr David Strain, who also served as an analysis author said that while there wasn't one treatment that would fix everyone with Long Covid, the initial results from the study were positive. “There isn’t a blood pressure tablet that fixes everybody... and similarly, there’s not one Long Covid treatment that’s going to fix everyone – but the fact that one treatment does fix something means that there’s bound to be other treatments out there that will fix others," he explained.
Nathalie Emmanuel and Garrett Hedlund have signed up to star in the Dracula-inspired horror-thriller The Bride. The Fast & Furious actress and Tron: Legacy actor will be directed by The Light of the Moon filmmaker Jessica M. Thompson in the project, which is being described as a contemporary horror-thriller inspired by Bram Stoker's Dracula. It tells the story of a young woman who is courted and swept off her feet, only to realise a gothic conspiracy is afoot. According to Deadline, executives at Screen Gems see the film as the start of a potential franchise and studio officials have fast-tracked production, with cameras set to roll at the end of summer. Australian filmmaker Thompson, who was first announced as the director of the project in June last year, shared the Deadline article on Instagram and wrote in the caption, "We’re making a movie! Pretty (bram) stoked about this one #nathalieemmanuel #garretthedlund #womeninfilm #femalefilmmakers #womeninhorror #dracula." She also shared the news on her Instagram Stories and wrote that the team she's assembled for the project is made up of "wildly talented humans" and added GIFs of a film camera, fireworks, and dripping blood. Blair Butler wrote the original script based on her pitch, with Thompson making revisions, and Emile Gladstone will serve as producer. Emmanuel, who is well-known for playing Missandei in Game of Thrones, will next be seen reprising her role as Ramsey, a British computer hacker, in Fast & Furious 9, or F9, when it is released next month after being delayed for a year due to the pandemic. Hedlund was mostly recently seen in The United States vs. Billie Holiday and his upcoming projects include The Ploughman, which is being directed by Ed Harris.
Clearview AI, the leading facial recognition company that provides its services to law enforcement, added 3 top professionals to its leadership team.
J.J. Abrams has confirmed he won't direct the upcoming Black Superman movie. Warner Bros. officials announced in February that the Star Wars: The Force Awakens director was producing a Black Superman movie and author and journalist Ta-Nehisi Coates was writing the screenplay, but no details were shared about the director or the lead actor. In an interview with Yahoo! Entertainment, Abrams confirmed that he will not be helming the superhero reboot. "I will not be directing that movie," he stated. "But I will say it's a project that means an enormous amount to us and when the time is right I really can't wait to talk about it, but unfortunately, that time is not now, but I look forward to that happening when it does." His confirmation comes shortly after The Hollywood Reporter published a report suggesting that Abrams is not being considered for the directing job because Warner Bros. and DC Comics officials feel it would be "tone-deaf" to hire him and they are actively seeking a Black filmmaker to take the reins. While no official announcements have been made about who will play Superman, Michael B. Jordan recently declared that he wasn't in the running for the role. In a separate interview with Collider, Abrams shared that he is unlikely to direct any of the DC films his production company Bad Robot has in the pipeline as he is keen to return to original ideas after a long run of directing franchises. "I feel like, as someone who started writing in television and telling original stories on film and in TV, it is something that I really do miss," he shared. "The few things that I'm working on now, as a writer, are original ideas. I just feel, as a director, I really would love to have my next projects be things that didn't pre-exist me necessarily." Abrams, who has directed two Star Wars films, two Star Trek movies, and a Mission: Impossible instalment, last helmed an original film with 2011's Super 8.
Scientists have discovered a link between the presence of specific bacterial genes in the gut and multiple diseases. Researchers from the Harvard Medical School and Joslin Diabetes Center analysed the genetic make-up of bacteria in the human gut and successfully linked groups of bacterial genes, known as "genetic signatures", to the presence of diseases and conditions such as coronary artery disease, cirrhosis of the liver, inflammatory bowel disease, colon cancer, and Type 2 diabetes. The findings showed that coronary artery disease, inflammatory bowel disease, and liver cirrhosis share many of the same bacterial genes, meaning people who have guts harbouring these genes seem more likely to have one or more of these conditions. In contrast, they found Type 2 diabetes has a microbiome signature unlike any other phenotype the team tested. The researchers said their study represents a significant advance in the understanding of the link between microbes in the gut and specific diseases, and could eventually pave the way for scientists to develop tests that could gauge a person's risk of a range of conditions using a stool sample. "This opens a window for the development of tests using cross-disease, gene-based indicators of patient health," said first author Braden Tierney. "We've identified genetic markers that we think could eventually lead to tests, or just one test, to identify associations with a number of medical conditions." The experts, who collected microbiome data from 13 groups of patients resulting in more than 2,500 samples for their study, have warned that their investigations require further research because it currently remains unclear whether these bacterial genes have a role to play in the development of diseases or are simply bystanders. Senior author Chirag Patel also explained their findings showed that it wasn't just the presence of specific bacterial families that indicated risk, but rather the strains and gene signatures of them that are the most important. The findings were published in Nature Communications.
The Covid-19 pandemic has put a spotlight on mental health, and perfectionism is yet another issue causing rising concern among health experts. Perfectionism is often defined as "the need to be or appear to be perfect, or even to believe that it's possible to achieve perfection". While it is usually viewed as a positive characteristic rather than a flaw, there are times when the pressure to avoid making mistakes becomes overwhelming and is detrimental to our health. Perfectionism can stop people from trying new things or completing tasks, especially when it comes to education, work, relationships or our appearance. It may mean we miss out on new opportunities because we are afraid of failing, and our own unrealistic expectations can lead to procrastination and anxiety. Perfectionism often triggers anxiety and leaves you feeling exhausted and unable to make decisions, with physical symptoms including an upset stomach, headaches, racing heart and tension in the neck and temples. Angela Bryant, the founder of independent business review site angelrated.com, has shared some important signs to look out for if you suspect you or someone else may be battling perfectionism: -Being highly critical of your own work and that of others, taking pride in spotting (and correcting!) tiny mistakes and imperfections. -Setting unrealistic standards that you expect others to meet. -Being driven by a fear of failure/of trying to prove that you are perfect. -Beating yourself up at the end of each day if you haven't achieved everything that you wanted to. -Procrastinating because you are so worried about starting and failing. As with many mental health issues, getting to the root of its cause is an important part of developing coping strategies. Angela believes looking back at childhood experiences is a good place to start. It's also helpful to pinpoint triggers to understand what is fuelling your perfectionism - are you afraid to fail at work? Or are you dreading upcoming exams? Have you had a bad relationship in the past? Getting to grips with exactly what is worrying you is crucial. Here are Angela's top tips for dealing with perfectionism: -Recognise what is driving your perfectionism and try to understand where it came from (your childhood, the media, etc). -Keep a list of examples of when you finished something that wasn't 'perfect' and nothing bad happened/it was still a success. -Break goals down into bite-size chunks so you don't fall into the all-or-nothing mindset of either wanting to complete everything or not do it at all. -Keep repeating the mantra progress, not perfection!
Dublin, May 18, 2021 (GLOBE NEWSWIRE) -- The "Healthcare/Medical Simulation - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Healthcare/Medical Simulation Market to Reach $5.9 Billion by 2027Amid the COVID-19 crisis, the global market for Healthcare/Medical Simulation estimated at US$2.1 Billion in the year 2020, is projected to reach a revised size of US$5.9 Billion by 2027, growing at a CAGR of 15.9% over the analysis period 2020-2027. Healthcare Anatomical Models, one of the segments analyzed in the report, is projected to record a 17.2% CAGR and reach US$2.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Web-based Simulators segment is readjusted to a revised 16.1% CAGR for the next 7-year period.The U.S. Market is Estimated at $619.7 Million, While China is Forecast to Grow at 15.2% CAGRThe Healthcare/Medical Simulation market in the U.S. is estimated at US$619.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1 Billion by the year 2027 trailing a CAGR of 15.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 14.4% and 13.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 11.5% CAGR.Healthcare Simulation Software Segment to Record 15.4% CAGRIn the global Healthcare Simulation Software segment, USA, Canada, Japan, China and Europe will drive the 15.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$286.5 Million in the year 2020 will reach a projected size of US$770.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$701.9 Million by the year 2027.Key Topics Covered: I. METHODOLOGYII. EXECUTIVE SUMMARY1. MARKET OVERVIEW Influencer Market InsightsWorld Market TrajectoriesImpact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS(Total 35 Featured): 3D SystemsCAECardionics, Inc.Gaumard Scientific CompanyKyoto KagakuLaerdal MedicalLimbs & ThingsMedaphorMentice ABOperative Experience, Inc.Simulab CorporationSimulaidsSynBone AGVirtaMed AGVRMagic Holding AG 3. MARKET TRENDS & DRIVERS4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Healthcare/Medical Simulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGRWorld Current & Future Analysis for Healthcare Anatomical Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGRWorld Current & Future Analysis for Web-based Simulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGRWorld Current & Future Analysis for Healthcare Simulation Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGRWorld Current & Future Analysis for Simulation Training Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGRWorld Current & Future Analysis for Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGRWorld Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGRWorld Current & Future Analysis for Military Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGRWorld Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR III. MARKET ANALYSIS IV. COMPETITION Total Companies Profiled: 35 For more information about this report visit https://www.researchandmarkets.com/r/dl972u CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Former champion Stan Wawrinka has pulled out of the French Open after failing to recover sufficiently from an operation he underwent on his left foot in March, a source told Reuters on Tuesday. The 36-year-old Swiss, who won the claycourt Grand Slam at Roland Garros in 2015, has not played on the Tour since his opening round loss in March. The three-times Grand Slam champion, a former world number three, then underwent a minor procedure on his left foot and at the time said he will be out for a few weeks.
We've got your back
The duchess wore the T-shirt in the trailer for Prince Harry and Oprah Winfrey’s new docuseries
If you’re not getting all the sleep you need, it might be time to reconsider what you’re snoozing on
Indoor gigs are finally back on the cards. Here’s where to have a jolly good giggle
Graham McGill must serve a minimum of 14 years after he was convicted of strangling the mother-of-11 with the cord from her dressing gown.
It will be the first time the contraptions will legally be allowed on the capital’s roads
EVgo, (or the "Company"), the nation’s largest public fast charging network for electric vehicles (EVs) and the first powered by 100% renewable energy, today announced the nomination of Patricia K. Collawn to join its Board of Directors upon the closing of its previously announced business combination with Climate Change Crisis Real Impact I Acquisition Corporation ("CRIS").
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
Stockholm, Sweden – Sinch AB (publ) – XSTO: SINCH Sinch held its annual general meeting on Tuesday 18 May 2021. Adoption of financial statements, appropriation of the company’s profit or loss and discharge from liability The meeting adopted the presented profit and loss statement and balance sheet as well as the consolidated profit and loss statement and consolidated balance sheet. In accordance with the proposal of the board of directors, the meeting resolved to not pay any dividend for the financial year 2020. The meeting further resolved to grant discharge from liability of the members of the board of directors, the CEO and the deputy CEO for the financial year 2020. Election of members of the board of directors, chairman of the board of directors and auditors The meeting resolved, in accordance with the nomination committee’s proposal, that the board of directors shall consist of six members elected by the meeting with no deputy members and resolved to re-elect Erik Fröberg, Renée Robinson Strömberg, Johan Stuart, Björn Zethraeus and Bridget Cosgrave and to elect Luciana Carvalho. Erik Fröberg was re-elected as chairman of the board of directors. Deloitte AB was re-elected as auditor. Remuneration to the board of directors and the auditors The meeting resolved, in accordance with the nomination committee’s proposal, on an annual remuneration of SEK 700,000 to each of the members of the board of directors who are not employed by the company and of SEK 1,500,000 to the chairman of the board of directors. Furthermore, it was resolved on an annual remuneration of SEK 100,000 to each of the members of the audit committee, of SEK 250,000 to the chairman of the audit committee, of SEK 50,000 to each of the members of the remuneration committee and of SEK 100,000 to the chairman of the remuneration committee. In addition, it was resolved that remuneration to the auditor is paid in accordance with approved invoices. The principles for the nomination committee and instructions for the nomination committee The meeting resolved on the principles for the nomination committee and instructions for the nomination committee in accordance with the nomination committee’s proposal. Guidelines for compensation to senior executives The meeting resolved on guidelines for compensation to senior executives proposed by the board of directors. Approval of the remuneration report The meeting resolved to approve the board of directors’ remuneration report. Authorization for the board of directors to resolve on new issues of shares The meeting resolved, in accordance with the board of directors’ proposal, to authorize the board of directors, on one or several occasions, until the next annual general meeting, to resolve on issues of new shares, and that such new issue can be performed with deviation from the shareholders’ preferential rights. The board of directors is entitled to resolve on share issues causing an increase of the company's share capital of at most 20 percent of the company's registered share capital at the time the board of directors first utilizes the authorization. The reason for the authorization and the reason for the possible deviation from the shareholders’ preferential rights is to enable capital raisings for the acquisition of companies, or parts of companies, and for the operations of the company. Resolution on share split and amendment to the articles of association The meeting resolved, in accordance with the board of directors’ proposal, on a share split 10:1 whereby each share is divided into ten shares, and that § 5 in the company’s articles of association is amended so that the number of shares shall be no less than 250,000,000 and no more than 1,000,000,000. The meeting further resolved to authorize the board of directors to determine the record date for the split of the company’s shares. Resolution on incentive program 2021 and issue of warrants and employee stock options The meeting resolved, in accordance with the board of directors’ proposal, to adopt an additional long term incentive program for senior executives and key employees within the Sinch group (“LTI 2021”). LTI 2021 comprises four series of warrants. Upon exercise of all warrants/stock options issued within the frame of LTI 2021, up to 323,000 shares (with reservation for any re-calculation) may be issued, equivalent to a maximum dilution of approximately 0.49 per cent of the shares and votes of the company. Upon full exercise of the warrants, the company’s share capital will increase with SEK 32,300. The calculations above have been based on the number of shares and votes in the company as of the date of the notice. Other information In order to prevent the spread of the coronavirus infection (COVID-19), the annual general meeting was conducted via a vote-by-post procedure and thus without the physical presence of shareholders, proxies or external parties. For further information, please contact Thomas HeathChief Strategy Officer and Head of Investor RelationsSinch AB (publ)Mobile: +46-722-45 50 55E-mail: firstname.lastname@example.org About Sinch Sinch brings businesses and people closer with tools enabling personal engagement. Its leading cloud communications platform lets businesses reach every mobile phone on the planet, in seconds or less, through mobile messaging, voice and video. Sinch is a trusted software provider to mobile operators, and its platform powers business-critical communications for many of the world’s largest companies. Sinch has been profitable and fast-growing since its foundation in 2008. It is headquartered in Stockholm, Sweden, and has local presence in more than 40 countries. Shares are traded at NASDAQ Stockholm: XSTO:SINCH. Visit us at sinch.com. This information was submitted for publication, through the agency of the contact person set out above, at 13:30 CEST on May 18, 2021. Attachment 20210518_Resolutions_from_AGM_2021_ENG